B. Habtemariam

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Pazdur, A. Al-Hakim, R. Justice, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

R. Pazdur, A. Farrell, L. Nie, 2018, The oncologist.

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.

D. Magen, Y. Frishberg, T. Mcgregor, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

M. Manoharan, S. Chong, K. Charissé, 2022, Drug Metabolism and Disposition.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

M. Manoharan, S. Chong, K. Charissé, 2022 .

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

A. Borodovsky, V. Goel, N. Najafian, 2020, Clinical Pharmacokinetics.

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

M. Sweetser, H. Attarwala, V. Goel, 2020, Clinical pharmacology and therapeutics.

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

P. Haslett, J. Lieske, D. Magen, 2021, Clinical journal of the American Society of Nephrology : CJASN.

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

M. Manoharan, S. Chong, K. Charissé, 2021, Drug Metabolism and Disposition.

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

A. Borodovsky, V. Goel, N. Najafian, 2020, Clinical Pharmacokinetics.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

V. Goel, G. Robbie, Sagar Agarwal, 2020, Clinical pharmacology and therapeutics.

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

J. Lieske, D. Magen, I. Bhan, 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1

J. Lieske, D. Magen, M. Sweetser, 2021, Kidney international reports.

Tocilizumab for Treatment of Severe or Life-Threatening Chimeric Antigen Receptor T Cell-Induced Cytokine Release Syndrome—FDA Approval Summary

A. Farrell, L. Nie, B. Habtemariam, 2018 .

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

M. Manoharan, S. Chong, K. Charissé, 2022 .

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Abstract 10974: Durable Reductions in Circulating Angiotensinogen and Blood Pressure Six Months After Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

Akshay S. Desai, G. Bakris, Jamie Harrop, 2021, Circulation.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.